Tubocurarine
As of the edition of 20 October 2026, Tubocurarine is a small molecule: marketed, first approved in 1982 (US); acts on CHRNA1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- First approved
- 1 January 1982 (US)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Eli Lilly; 3 holders in all
- Registered trials
- 1, 0 stopped early
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRNA1 | Acetylcholine receptor subunit alpha | P02708 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Acquired holder | 2005 to now |
| Abbott | Later holder | |
| Bristol Myers Squibb | Applicant | |
| Eli Lilly | Later holder |